
Amarin Corporation plc
Amarin Corporation plc (AMRN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · AMRN · as of Jun 8, 2026
Key Statistics
Explore Amarin Corporation plc Data
amrn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 18 · Buy rate: 16.7%
The AMRN analyst consensus is Hold, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month price target is $2.17, representing -84.42% downside from the current price of $13.93.
Competitors & Peers
amrn competitorsStock Performance
Full HistoryAbout Amarin Corporation plc
Amarin Corporation plc a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, L…
what is amarin corporation plc · amrn stock overview · amarin corporation plc company profile · who is amarin corporation plc ceo · amrn NASDAQ · amarin corporation plc headquarters · amarin corporation plc business segments
About Stock Overview & Key Data
Amarin Corporation plc (AMRN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 1, 1993. As of the latest trading session, AMRN stock price is $13.93, with a market capitalization of $288.1M. The stock has returned +12.98% over the past 12 months and -0.21% year-to-date.
According to 18 Wall Street analysts, the consensus rating for Amarin Corporation plc stock is Hold, with an average 12-month price target of $2.17. In fiscal year 2025, Amarin Corporation plc reported revenue of $213.6M and net income of -$38.8M. For detailed data — including Amarin Corporation plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Amarin Corporation plc (AMRN) stock price is $13.93. The stock is traded on NASDAQ under the ticker symbol AMRN. The 52-week range is $11.65 – $20.90.